# Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial

> **NCT04361643** · PHASE4 · UNKNOWN · sponsor: **Hospital Universitario Getafe** · enrollment: 120 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04361643
- **Lead sponsor:** Hospital Universitario Getafe
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-27
- **Primary completion:** 2021-08-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2020-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04361643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04361643, "Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04361643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*